Intrinsic Bioprobes | GenomeWeb

Intrinsic Bioprobes

By Adam Bonislawski
Proteomics in 2011 continued its long, hard slog toward the clinic, battling now-familiar challenges like sluggish test sales, unproven platforms, and the vagaries of the regulatory process.

Thermo Fisher Scientific said this week that it has acquired protein biomarker firm Intrinsic Bioprobes, adding to its clinical proteomics portfolio.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today announced it has purchased proteomics sample preparation firm Intrinsic Bioprobes for an undisclosed amount.

EGFR has emerged as a primary area of interest in cancer research, with biopharmaceuticals like Imclone's Erbitux and Amgen's Vectibix targeting the protein, but its multiple isoforms have made it difficult to predict these drugs' effectiveness, said Yale professor Nita Maihle.

The findings suggest that guidelines for chronic kidney disease testing, which have come under increased scrutiny in recent years, could benefit from including albumin and cystatin C levels in definitions of the disease.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.